Skip to main content
CELZ logo

CELZ · Creative Medical Technology Holdings, Inc. · Documents

Track CELZ — free
$0.46 -0.01 (-2.42%)
Market Cap
$3.34M
Shares
7.60M
Volume · Nov 19 81.51K Avg daily vol (3M) 637.41K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $6000 down 45.5% 10-K filed Mar 20, 2026 Quarterly report FY2026 Q3 Revenue $0 10-Q filed Nov 6, 2026
2026
Nov 13
Current report 8-K Events of Nov 10
Nasdaq bid-price deficiency opens compliance grace period

Creative Medical Technology Holdings, Inc. received Nasdaq notice on November 10, 2026 after its bid price stayed below $1.00 per share for 30 business days. It has until May 10, 2027 to regain compliance for at least ten consecutive business days.

Delisting notice or listing transfer
2 source passages
On November 10, 2026, Creative Medical Technology Holdings, Inc. (the “Company”) received a letter from The Nasdaq Stock Market stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of the Company’s common stock was below $1.00 per share for 30 consecutive business days. Pursuant to Nasdaq’s Listing Rules, the Company has a 180 day grace period, until May 10, 2027, during which the Company may regain compliance if the bid price of its common stock closes at $1.00 per share or more for a minimum of ten consecutive business days. Open the document at this passage
Nov 10
Proxy statement DEF 14A
Five directors and evergreen share provision face stockholders

Creative Medical Technology Holdings, Inc. stockholders will vote on December 28, 2026 to elect five directors and approve an evergreen provision adding up to 5% of outstanding common shares annually from January 1, 2027 through January 1, 2031.

Read from the first part of this long document
4 source passages
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. We are pleased to invite you to attend our 2026 Annual Meeting of Stockholders to be held on December 28, 2026, at 9:00 a.m. Pacific Standard Time at 440 Stevens Avenue, Suite #200, Solana Beach, CA 92075 (the “Annual Meeting”). To elect five directors to our Board of Directors to serve until the next Annual Meeting of Stockholders or until their successors have been duly elected or appointed and qualified To approve an amendment to our 2021 Equity Incentive Plan (the “Equity Plan”) adopting an evergreen provision by which the number of reserved shares of Common Stock available for issuance under the Equity Plan will automatically increase on January 1, 2027 and on each subsequent January 1 through and including January 1, 2031, by up to 5% of the total number of shares of Common Stock issued and outstanding on December 31 of the immediately preceding calendar year Open the document at this passage
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Net loss widens to $2,663,478

Creative Medical Technology Holdings reported no revenue and a $2,663,478 net loss for the three months ended September 30, 2026, versus $1,235,934 a year earlier. Available cash and US Treasuries totaled $6,845,741.

Revenue $0 Net loss $2.67M Diluted EPS -$0.40
Read from the MD&A section
4 source passages
Creative Medical Technology Holdings, Inc. No revenues were generated during the three-month periods ended September 30, 2026 and 2025. For the reasons stated above, our net loss for the three-months ended September 30, 2026, was $2,663,478 in comparison with a net loss of $1,235,934 for the comparable period a year ago. As of September 30, 2026, we had $6,845,741 of available cash and US Treasuries and positive working capital of approximately $6,643,493. Open the document at this passage
Sep 25
Current report 8-K Events of Sep 24
Entered into a material agreement, Unregistered sale of equity

On September 24, 2026, Creative Medical Technology Holdings, Inc. purchased 4,000,000 BioDefense, Inc. shares for $200,000 and 1,000,000 company shares, increasing its ownership to 16,000,000 shares, or 80%.

Aug 7
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $0 Net loss $1.51M Diluted EPS -$0.41
Jul 14
Proxy statement DEF 14A Meeting Aug 28, 2026
Proxy statement AI summary on its way
May 8
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $0 Net loss $1.41M Diluted EPS -$0.38
Mar 20
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $6000 ▼ 45.5% Net loss $6M Diluted EPS -$2.52
2025
Mar 14
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $11K ▲ 22.2% Net loss $5.49M Diluted EPS -$3.71
2024
Showing 1–50 of 105 documents
Key facts CIK 1187953 CUSIP 22529Y408 13F (30d) 21 filings 20 filers Visit website Investor relations